Clinical trials: Second-Line
Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules
- Trial name
- NCT00006227
- Testing
- Paclitaxel
- Where
- 98 sites in United States, Japan
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Nonsquamous Nonsmall Cell Neoplasm of Lung
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC).
- Trial name
- TEAM (NCT01161173)
- Testing
- Erlotinib
- Where
- 36 sites in Belgium, Luxembourg
- Volunteers
- 347 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Helicobacter Pylori Infection
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available.
- Trial name
- NCT02596620
- Testing
- Nexium, Amolin, Cravit
- Volunteers
- 164 people
- Sponsor
- Chang Gung Memorial Hospital
Esophageal Cancer
Phase II Study of Irinotecan and Panitumumab
This study proposes a single-arm, phase II study of irinotecan with panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma.
- Trial name
- NCT00836277
- Testing
- Panitumumab, Irinotecan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weijing Sun, MD, FACP
Locally Advanced or Metastatic Renal Cell Carcinoma
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after…
- Trial name
- CaboPoint (NCT03945773)
- Testing
- Cabozantinib
- Where
- 40 sites in Austria, France and 5 more
- Volunteers
- 127 people
- Sponsor
- Ipsen
Breast Adenocarcinoma, HER2/Neu Negative
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back.
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT02037529
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 39 sites in United States
- Volunteers
- 201 people
- Sponsor
- Academic and Community Cancer Research United
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and…
- Trial name
- NCT03016871
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer, Skin Rash
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with…
- Conditions
- Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer
- Trial name
- STEPP (NCT00332163)
- Testing
- Panitumumab, Irinotecan, FOLFIRI
- Volunteers
- 95 people
- Sponsor
- Amgen
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer…
- Trial name
- TIME (NCT01664533)
- Testing
- Erlotinib
- Where
- 21 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
As < 10% of the necessary patients required by the protocol were recruited and the data were not intended to support a labeling claim, it was determined that the abbreviated clinical study report (CSR) was the appropriate…
- Trial name
- CANVAS (NCT01521143)
- Testing
- Cvac
- Where
- 8 sites in United States, Australia
- Volunteers
- 91 people
- Sponsor
- Prima BioMed Ltd
Non Small Cell Lung Cancer Metastatic
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
BOOSTER is a randomised, controlled, phase II trial comparing osimertinib and bevacizumab versus osimertinib alone as second-line treatment in patients with stage IIIb-IVb non-small cell lung carcinoma (NSCLC) harbouring…
- Trial name
- BOOSTER (NCT03133546)
- Testing
- Osimertinib, Bevacizumab
- Where
- 25 sites in Ireland, Netherlands and 4 more
- Volunteers
- 155 people
- Sponsor
- ETOP IBCSG Partners Foundation
HIV Infections
Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
The strategy to support virological suppression on second-line antiretroviral treatment (ART) includes the provision of ART that has a low pill burden, good tolerability, low toxicity, is easily monitored, has a high barrier to…
- Trial name
- ARTIST (NCT03991013)
- Testing
- Dolutegravir 50 mg
- Where
- South Africa
- Volunteers
- 192 people
- Sponsor
- University of Cape Town
Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Cancer
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
This was an open-label, multi-centre, uncontrolled, exploratory trial with a duration of 12 months in two cohorts. The trial aimed to investigate Degarelix as a second-line hormonal treatment in Prostate Cancer patients who…
- Trial name
- NCT00738673
- Testing
- degarelix
- Where
- 15 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Ferring Pharmaceuticals
HIV Infection
ODYSSEY (PENTA 20)
A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.
- Trial name
- NCT02259127
- Testing
- Dolutegravir, Standard of Care
- Where
- 28 sites in Germany, Portugal and 6 more
- Volunteers
- 792 people
- Sponsor
- PENTA Foundation
AIDS, HIV Infections
CSP #512 - Options in Management With Anti-Retrovirals
This 'pragmatic' trial is a 2X2 open randomized study of patients in advanced HIV disease who have failed on conventional Highly Active Antiretroviral Therapy (HAART) regimens including all three classes of anti-HIV drugs.
- Trial name
- OPTIMA (NCT00050089)
- Testing
- No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 368 people
- Sponsor
- US Department of Veterans Affairs
Breast Cancer
MEtronomic TrEatment Option in Advanced bReast cAncer
This is a multi-center, randomized phase II trial that will randomise women with ER-positive, HER2-negative (Human Epidermal Growth factor Receptor 2-negative) metastatic or locally relapsed breast cancer in a ratio of 1:1 to…
- Trial name
- METEORA-II (NCT02954055)
- Testing
- Paclitaxel, Cyclophosphamide, Capecitabine
- Where
- 20 sites in Italy
- Volunteers
- 140 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer
Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer
This 2 arms study will compare the efficacy and safety of treatment with sequential erlotinib plus docetaxel therapy versus docetaxel alone as second line treatment in patients with recurrent non-small cell lung cancer.
- Trial name
- TARSEQ (NCT01350817)
- Testing
- Erlotinib + docetaxel, Docetaxel
- Where
- 30 sites in France
- Volunteers
- 156 people
- Sponsor
- University Hospital, Limoges